• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / Citizens Speak / HPV Vax / United States Concerns / SANE Vax to Jack Stapleton, Chairman VRBPAC (vaccines and related biological products advisory committee)

SANE Vax to Jack Stapleton, Chairman VRBPAC (vaccines and related biological products advisory committee)

August 30, 2011 By Norma Leave a Comment

 

October 19, 2010

Jack Stapleton, M.D., Chair 
Vaccines and Related Biological Products Advisory Committee 
University of Iowa Hospital Clinic 
200 Hawkins Drive 
Iowa City, Iowa 52242

SUBJECT:  Valid endpoint and reliable HPV genotyping for expanded use   proposal of GardasilTM vaccine

Dear Dr. Stapleton:

S.A.N.E. Vax, Inc. is a non-profit organization established to promote safe, affordable, necessary and effective vaccines and vaccination practices. We have been informed by the news media that the Vaccines and Related Biological Products Advisory Committee will meet on Nov. 17 to discuss the effectiveness of GardasilTM vaccination of males and females to prevent anal dysplasia and anal cancer, in fact to initiate a regulatory process which may lead to FDA expanded use approval allowing GardasilTM to be marketed as a cancer vaccine to the general American population, including both men and women.

Although detailed information has not been provided, the vaccine manufacturer seems to propose using ‘anal dysplasia and anal cancer’ as a single primary endpoint for evaluating the effectiveness of this virus vaccine.

The SaneVax team believes this primary endpoint is inappropriate for the following reasons:

  1. Anal dysplasia, also known as anal intraepithelial neoplasia (AIN),1 is a term representing collectively various grades of precancerous changes, also referred to as epithelial dysplasia, grades I, II and III. There is considerable inter-observer variation in the reporting of this condition even by experienced histopathologists.1 If anal dysplasia is used as an endpoint for evaluation in the clinical trials, the grades of dysplasia must be stratified in the vaccinated group and in the placebo group so that the percentage of a particular grade of anal dysplasia can be compared between the vaccinated and the placebo-receiving subjects for efficacy calculation. The vaccine manufacturer must present data to show the percentage of spontaneous regression of each grade of anal dysplasia in the trial human population so that the self-reversing lesions in a low grade of dysplasia will not introduce bias in the calculation of the effectiveness of the vaccine.
  2. A number of risk factors have been implicated in the development of anal dysplasia, with the most significant being anal HPV infection, receptive anal intercourse, HIV infection, and lower CD4+ levels. The subjects enrolled into the clinical trial programs for the evaluation of the efficacy of GardasilTM to prevent anal dysplasia must have similar risk factors. Only when all risk factors have been equalized, a reduced rate of anal dysplasia observed in the vaccinated group, if any, compared to the placebo-receiving group, can be attributed to the effects of Gardasil vaccination. It is well known that different HPV genotypes pose different levels of cancer risk. Reliable HPV genotyping is essential in stratification of risk factors to anal dysplasia among enrolled trial subjects. Since PCR/short target DNA sequencing is the only reliable method for HPV detection and genotyping, 2 all pre-vaccination and post-vaccination HPV infections in these trial subjects must be ruled out by PCR or confirmed by short target sequencing genotyping. It is obvious that trial subjects infected by different genotypes of HPV will have different risks in developing anal dysplasia independent of the effects of GardasilTM vaccination.
  3. The vaccine manufacturer must demonstrate the effectiveness of GardasilTM in preventing each grade of anal dysplasia. The criteria of diagnosis for each grade of anal dysplasia must be clearly defined and the diagnosis must be consistently reproducible among at least three board-certified pathologists.
  4. It is well known that anal dysplasia is largely a pathology found in patients who have a history of practicing receptive anal intercourse.3 The clinical trial data derived from study subjects practicing anal sex should not be extrapolated to  populations which do not practice anal sex. If the vaccine manufacturer claims that GardasilTM is also effective in preventing anal dysplasia in the populations which do not practice anal sex and intends to market GardasilTM to the latter group, then trial subjects who do not practice anal sex must be recruited for the clinical studies, independent of those studies in which the trial subjects are practitioners of anal sex.
  5. If the vaccine manufacturer intends to claim that GardasilTM can prevent the development of anal cancer, then anal cancer must be used as the primary endpoint to determine the efficacy of the vaccine. Precancerous changes, such as anal dysplasia grade I, grade II or gradeIII, should not be used as a surrogate endpoint for anal cancer in the clinical trials.
  6. If the vaccine manufacturer intends to claim that GardasilTM can prevent anal infection by vaccine-relevant HPV genotypes, then a reliable method, namely a PCR system with short target DNA sequencing2 must be used to detect HPVDNA in the anal specimens and for HPV genotyping.

Our research also revealed that an inappropriate primary endpoint was used in the evaluation of GardasilTM to prevent cervical cancer, and that no reliable HPV genotyping methods were used to validate the efficacy of GardasilTM to prevent genotype-specific HPV infections in women. A letter to the FDA commissioner, requesting that the FDA rescind approval of GardasilTM as a vaccine for prevention of cervical cancer, is enclosed herewith for your reference.

In the interest of promoting and protecting the public health, S.A.N.E. Vax, Inc. respectfully requests that expanded use for GardasilTM as an anal cancer preventive vaccine be delayed, until such time as the efficacy of the vaccine is properly evaluated using the true endpoint for anal cancer prevention, and a reliable HPV genotyping method for detection of type-specific HPV infections.

I am looking forward to receiving your response to this reasonable request on behalf of medical consumers around the world.

Yours respectfully,

Norma Erickson, President 
S.A.N.E. Vax, Inc. 
154 Cecil Drive 
Troy MT 59935
 
Signed on behalf of the Board of Directors, S.A.N.E. Vax, Inc. 
Leslie Carol Botha, Vice President of Public Relations 
Janny Stokvis, Vice President of Research 
Rosemary Mathis, Vice President, Victim Support 
Freda Birrell, Secretary 
Linda Thompson, Treasurer 

References

  1. Carter PS, Sheffield JP, Shepherd N, Melcher DH, Jenkins D, Ewings P, Talbot I, Northover JM. Interobserver variation in the reporting of the histopathological grading of anal intraepithelial neoplasia. J Clin Pathol. 1994;47:1032-1034.
  2. National Cancer Institute. HPV Genotyping. Solicitation Number: NCI-100143-MM. August 2, 2010. https://www.fbo.gov/index?s=opportunity&mode=form&id=da396b97ad6eb7ec4f7d511f85d9e325&tab=core&_cview=0
  3. Moscicki AB, Hills NK, Shiboski S, Darragh TM, Jay N, Powell K, Hanson E, Miller SB, Farhat S, Palefsky J. Risk factors for abnormal anal cytology in young heterosexual women. Cancer Epidemiol Biomarkers Prev. 1999;8:173-178. 

CC:   Vaccines and Related Biological Products Advisory Committee:

Donald Jehn, M.S., Designated Federal Officer 
Denise Royster, Committee Management Specialist 
Ambrose Cheung, M.D., 
Vicky Debold, Ph.D., R.N. 
Frank DeStefano, M.D., M.P.H.
Anna Durbin, M.D. 
Peter Gilbert, Ph.D. 
Gregory Gray, M.D., M.P.H. 
Margaret Rennels, M.D. 
Jose Romero, M.D. 
Pablo Sanchez, M.D. 
Gary Schoolnik, M.D. 
Carol Tacket, M.D. 
 
Dr. Margaret Hamburg, M.D., Commissioner 
U. S. Food and Drug Administration (FDA)

Related

Filed Under: United States Concerns Tagged With: Anal Cancer, expanded use proposal, Gardasil, valid endpoint, VRBPAC

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Lauren from Rochdale, Lancashire, UK

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

HPV Vaccine: Miracle or menace?

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in

 

Loading Comments...